On July 16, Definium Therapeutics rose 5.1% in pre-market trading, trading at $48.0/share, with turnover of $62,900. The stock continues to rally as multiple positive catalysts sustain buying momentum.

On the news front, the company previously announced that its core candidate DT120 oral disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful superiority over placebo. Subsequently, Definium successfully completed an $805 million follow-on offering with underwriters fully exercising the overallotment option, with proceeds earmarked for DT120 commercialization preparation and pipeline advancement. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating. With the current share price still trading below the upgraded target, market buying pressure continues.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)